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Plexiform ﬁbromyxoma tumor (PFT) is an exceedingly rare tumor, particularly in children where only
four cases have been reported to date. The patient reported herein presented with abdominal pain and
vomiting related to gastric outlet obstruction caused by a large, polypoid PFT. We describe the clinical
features, diagnostic evaluation, and surgical treatment of this rare tumor in our patient. Further, we
review the literature of FPT to bring attention to this rare gastric tumor to the Pediatric Surgeon.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Case report
A 9 year old female presented with a several month history of
intermittent abdominal pain described as periumbilical in location,
without triggering or relieving factors, and of short duration. Two
months prior to presentation she developed associated nausea and
vomiting, resulting in a 4.5 kg weight loss. The vomitus was free of
coffee-ground material, blood, and bile. She was treated with anti-
emetics without beneﬁt and was treated empirically for giardiasis
without beneﬁt. The symptoms were increasing in frequency and
severity prompting referral to gastroenterology, whence she un-
derwent esophagogastroduodenoscopy (EGD) that demonstrated a
large polypoid antralmass; a biopsy showed prominent granulation
tissue suggestive for a pyogenic granuloma. She was referred to our
institution for further evaluation and treatment.
At initial assessment, the patient’s physical exam was unre-
markable except for tachycardia and mild epigastric tenderness.
Medical and family histories were unremarkable. Admission labo-
ratory studies, including complete blood count, liver panel, and
serum electrolytes, were normal except for mild hypochloremia).
Inc. This is an open access article u(Cl ¼ 97 mmol/L, normal 98e120 mmol/L) and mild alkalosis
(CO2 ¼ 31 mmol/L, normal 22e29 mmol/L) consistent with her
history of vomiting. The patient was admitted, made NPO, and
started on intravenous ﬂuids for resuscitation.
Upper gastrointestinal series demonstrated a large mass with a
broad base attachment to the posterior wall of the distal stomach
and additional ﬁndings of high-grade partial gastric outlet
obstruction (Fig. 1A). Computed tomography (CT) scan further
deﬁned the 4 cm heterogeneously enhancing, predominately
intraluminal mass in the distal stomach without ﬁndings to suggest
external invasion or metastatic disease (Fig. 1B and C).
Following rehydration and correction of electrolyte abnormal-
ities, the patient was taken to the operating room where EGD was
performed with surgery in attendance to better assess the tumor
prior to surgical intervention and to determine if endoscopic
removal was possible. A large, polypoid mass arising from the
posterior antral wall was noted to obstruct the pyloric channel
(Fig. 2A). The base of the tumor could not be visualized and snaring
the mass was deemed too risky. Thus, a laparotomy was then per-
formed providing exposure for anterior gastrotomy, reduction of
the polyp from the duodenum, and subsequent resection at the
base from the posterior gastric wall.
Pathology demonstrated a plexiform ﬁbromyxoma with
extensive surface ulceration (Fig. 2B). Immunohistochemicalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Radiographic ﬁndings. UGI series demonstrated a large mass with a broad base attachment to the posterior wall of the distal stomach resulting in high-grade partial gastric
outlet obstruction (A), the edge of the tumor is highlighted with arrows. The tumor was better delineated on CT scan (B, coronal view; C, axial view).
M.W. Morris et al. / J Ped Surg Case Reports 4 (2016) 38e41 39markers further supported the diagnosis with spindle cells stain-
ing positive for smooth muscle actin and calponin, and focal
staining with desmin and CD10 (a marker for acute lymphoblastic
leukemia, but also found in stromal tumors). The lesional cells
were negative for antibodies found in GISTs, including DOG1
(discovered on GIST-1, a chloride channel protein), CD117 (C-kit, a
tyrosine kinase receptor), and CD34 (a hematopoietic progenitor
cell antigen). The tumor cells were also negative for antibodies
found in neuronal tumors S-100 (identiﬁes tumors of neuro-
ectodermal origin) and GFAP (glial ﬁbrillary acidic protein). Tumor
cells were negative for cytokeratin and ALK1 (activin receptor-like
kinase 1). In situ hybridization was negative for EBER (Eps-
teineBarr encoding region), excluding lymphoma. No acid fast
bacilli were noted on special stains.
The patient did well postoperatively with resolution of symp-
toms and was discharged home on postoperative day 7. She has
remained symptom free for 4 months of follow-up and has gained
4.7 kg. Although PFTs are benign and recurrence has not be re-
ported, we plan on a follow-up endoscopy 6 months from the time
of surgical removal.Fig. 2. Endoscopic and pathological features of the tumor. At endoscopy a large, friable, lo
tumor showed extensive surface ulceration (B). Hematoxylin and eosin stained sections of th
a plexiform growth pattern extending into the gastric wall (C, 4magniﬁcation). Loose strom
20 magniﬁcation).2. Discussion
First describe in 2007 by Takahashi et al., plexiform ﬁbromyx-
oma tumor (PFT) is a rare mesenchymal tumor with only 32 cases
reported to date in the English literature (Table 1) [1e16]. Alter-
natively referred to as plexiform angiomyxoid tumor, gastric
ﬁbromyxoma, and plexiform angiomyxoid myoﬁbroblastic, PFT is
the preferred nomenclature by the World Health Organization
classiﬁcation of tumors of the digestive system [17]. The tumors are
characterized by a plexiform growth pattern, a myxoid stroma rich
in small vessels, and the myoﬁbroblastic nature of the tumor cells
[1]. While some tumors may contain cells with ﬁbroblastic or
smooth muscle characteristics, myoﬁbroblastic cells are the pre-
dominant cell type in the majority of reported tumors [6].
Plexiform ﬁbromyxomas have been reported both in adults and
children with an age range from 7 years to 75 years (mean age of
40.3  19.0 years; median age of 42.5 years). Tumors are more
commonly reported in adults then in children, with an adult-to-
child ratio of approximately 5:1. There is no gender predisposition,
with a male-to-female ratio of approximately 1:1 [1e16].bulated mass was seen ﬁlling the pyloric antrum and obstructing the pylorus (A). The
e mass demonstrate classic features of plexiform ﬁbromyxoma. The lesion is arranged in
a separates numerous small vessels (D, 10magniﬁcation) and bland spindled cells (E,
Table 1
Clinical features of reported patients with PMAT.
Ref Gender Age (yr) Symptoms Location Ulcerated Size (cm)* Treatment Outcome
1 M 50 Abdominal pain Antrum Y 4 DG nd
M 68 Incidental Antrum 4.5 DG Alive no tumor (12 mo)
2 F 50 Nausea Antrum Y 1.9 WR Alive no tumor (3 mo)
3 M 61 Hematemesis Antrum Y 3.7 DG Alive no tumor (3 mo)
4 F 19 Mass Antrum 4.5 DG Alive no tumor (9 mo)
M 46 UGIB Antrum Y 3.5 DG Alive no tumor (4 mo)
5 F 38 UGIB Antrum Y 3 DG nd
M 62 Weight loss Antrum 4 PG nd
F 75 Unknown Antrum Y 5 STG Died unknown cause (2 mo)
F 65 Weight loss, ulcer Antrum, DB Y 5 PG Died unknown cause (14.5 yr)
M 33 Anemia Antrum Y 5.5 DG Alive no tumor (19.7 yr)
M 43 UGIB Antrum Y 5.5 PG Alive no tumor (18.4 yr)
F 56 Unknown Antrum, DB 5.5 PG Alive no tumor (19.9 yr)
M 50 Gastric outlet obstruction,
anemia
Antrum, DB 7 DG Alive no tumor (25.5 yr)
M 21 Anemia Antrum, DB Y 9 Antrectomy Alive tumor status unknown (22 yr)
F 16 Hematemesis Antrum Y 10 DG Alive tumor status unknown (3 yr)
F 30 Gastric ulcer Antrum Y 10 DG Alive tumor status unknown (24 yr)
F 7 Vomiting, mass Antrum, DB 15 WR nd
6 M 23 Abdominal pain, melena Antrum, DB 14 PG Alive no tumor (12 mo)
7 F 23 UGIB Antrum Y 8 DG nd
8 F 54 Dyspepsia, vomiting Fundus Y 1.5 ER Alive no tumor (6 mo)
9 M 34 Abdominal pain, mass Antrum 3.5 DG nd
10 F 35 Incidental [CT] Antrum Y 4 surgery Alive no tumor (12 mo)
11 M 52 Dyspepsia Antrum Y 3.5 WR Alive no tumor (5 mo)
12 M 47 Asymptomatic Body Y 3 WR Alive no tumor (6 yr)
F 63 Asymptomatic Body Y 2.2 ER Alive no tumor (1 mo)
13 F 42 Abdominal pain anemia Antrum Y 12.9 DG Alive no tumor (3 wk)
14 M 60 Epigastric pain Antrum 2 PG Alive no tumor (12 mo)
15 M 32 Asymptomatic Antrum 3.4 PG Alive no tumor (3 yr)
16 F 16 Incidental Esophagus nd surgery Alive no tumor (14 mo)
F 11 Anemia Antrum, DB Y 3.5 DG Alive no tumor (15 mo)
Our case F 9 Gastric outlet obstruction Antrum Y 5 PG Alive no tumor (6 mo)
Size (*) is expressed as the length of the longest axis of the tumor; DB, duodenal bulb; DG, distal gastrectomy; ER, endoscopic resection; nd, no data; PG, partial gastrectomy;
STG, sub-total gastrectomy; UGIB, is upper gastrointestinal bleeding (including hematemesis and ulcers leading to melena); WR, wedge resection.
M.W. Morris et al. / J Ped Surg Case Reports 4 (2016) 38e4140Clinical presentation of PFT varies from an incidental ﬁnding to
bowel perforation requiring emergency surgical intervention
[1,10,12,15,16]. Presenting clinical features were described in 31 of
the 32 reported cases. The most commonly reported ﬁndings
included upper gastrointestinal bleeding (melena and hematem-
esis) and abdominal pain and dyspepsia, both seen in 23% of pa-
tients. Other reported symptoms include anemia, nausea and
vomiting, gastric ulcer, and weight loss. Vomiting due to gastric
outlet obstruction by the tumor was reported in two patients. PFT
occurred as an asymptomatic incidental ﬁnding in 20% of patients,
including three during screening endoscopy, two by computed to-
mography for unrelated complaints, and one during cholecystec-
tomy [1,10,12,15,16].
The vast majority of PFT reported have been located in the
gastric antrum (88%), at times also involving the duodenal bulb
(22%). Case reports have documented involvement of the gastric
body (2, 6%) and fundus (1, 3%) [8,12]; the only report of PFT found
outside the stomach was an incidental PFT of the esophagus (3%)
identiﬁed by imaging for an unrelated complaint [16]. Tumors can
involve the stomach from the serosa to the submucosa [5]. When
mentioned, most PFTs present as a submucosal mass (75%);
polypoid lesions account for 20% and isolated serosal lesions ac-
count for 5%. Extra-gastric serosal extension is reported in 22% of
submucosal tumors highlighting their ability to be transmural;
gastric perforation due to tumor extension through the serosa has
been reported [1]. The tumors are not encapsulated andmay appear
as a nodular or granular mass when they extend through the mu-
cosa or serosa. Fully two-thirds of the tumors are ulcerated
explaining the high rate of bleeding associated with these lesions.
The size of the tumors range from 1.5-cm to 15-cm in longest axis
(mean of 5.6  3.5-cm and median of 4.5-cm) [1e16].The differential diagnosis of PFT contains other tumors that
present as a submucosal gastric mass including gastrointestinal
stromal tumors (GIST), neuronal tumors (schwannoma and
neuroﬁbroma), smooth muscle tumors (leiomyoma and leio-
myomsarcoma), and ﬁbroblastic tumors (solitary ﬁbrous tumor,
desmoid ﬁbromatosis, and inﬂammatory ﬁbroid polyp). Micro-
scopic criteria for diagnosis of PFT includes a plexiform growth
pattern, proliferation of bland-appearing spindle cells separated
by an abundant intracellular myxoid matrix, and a stroma rich in
Alcian blue positive, small vessels [1]. Immunohistochemistry is
essential for establishing the diagnosis of PFT. Summary of the
reported cases shows that PFT are positive for markers of myo-
ﬁbroblastic differentiation (smooth muscle actin [90%] and
vimentin [100%]) and negative for markers of GIST tumors (C-kit,
CD34, and DOG1) and neuronal tumors (s100). A number of
other markers that have been investigated in small numbers,
positive results were found for caldesmon and calponin;
negative results were found for ALK1, catenin, cytokeratin,
epithelial membrane antigen, neuron-speciﬁc enolase, and
neuroﬁlament. Mixed results were found for desmin (positive in
56%) and CD10 (positive in 20%). When studied, these tumors
have low mitotic activity (0e4 mitoses per 50 high power ﬁelds)
and low Ki-67 index (most <2%, one case had 6%)
[1,2,4,6,8,9,12,13,15].
Treatment primarily consists of surgical excision (94%), whereas
endoscopic resection has be performed in two cases [8,12]. Surgical
technique is dictated by location, size, and depth of the mass. Distal
gastrectomy (44%) is the most commonly reported surgery, fol-
lowed by partial gastrectomy (22%), wedge resection (13%),
antrectomy (3%), and subtotal gastrectomy (3%); surgery type was
not speciﬁed in 9%.
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follow-up. Overall time of follow-up ranged from 1 month to 25.5
years (mean 4.8 years, median 1 year). Three patients (12%) died of
causes unrelated to the tumor from 2 months to 25.5 years
following resection [5], 3 patients (12%) were alive with unknown
tumor status from 3 years to 24 years following resection [5], and
20 patients (76%) were alive without tumor recurrence 1 month to
20 years following resection [1e6,8,10e16]. To date there have been
no reported cases of metastatic disease resulting from PFT.
3. Conclusion
We report only the ﬁfth plexiform ﬁbromyxoma in a child.
Symptoms and signs of PFT are non-speciﬁc, the tumor is usually
identiﬁed with radiologic imaging, and diagnosis based on histo-
logical ﬁndings. Treatment is surgical; metastasis and recurrence of
tumor have not been reported with long-term follow-up.
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